Today is the last day on which TO3 series CLS subscription warrants can be traded

Today, April 21, 2022, is the last day on which subscription warrants from the TO3 series (the “subscription warrants”) issued by Clinical Laserthermia Systems AB (publ) (“CLS” or the “Company”) in connection with the rights issue of units and the directed issue of units carried out by the Company in April 2021 can be traded. The subscription warrants are traded on Nasdaq First North Growth Market. One (1) subscription warrant provides the right to subscribe for one (1) new class B share in CLS at a price of SEK 3.50. In the case of full exercising of all the subscription warrants, CLS will receive approximately SEK 35.6 million before issue costs.

Instructions on how to subscribe for CLS shares by exercising the subscription warrants are available in the press release published by CLS on April 11, 2022.

Holders who have their subscription warrants registered with a trustee (holdings in a share deposit account, an ISK investment account or an endowment insurance) must provide notification of the exercising of the subscription warrants by contacting the trustee and following the trustee’s instructions regarding subscription and payment. This should be done well in advance of April 25, 2022 as different trustees have different processing times.

Holders who have their subscription warrants registered directly in their name (holdings in a securities (VP) account) provide notification of the exercising of subscription warrants by completing and submitting the exercise notification form, so that the notification form is received by the issuing institution Aqurat Fondkommission by no later than April 25, 2022. The notification form is available on the respective websites of the Company, the issuing institution and Redeye AB (www.clinicallaser.com, www.aqurat.se, www.redeye.se). Please note that payment for the new shares must be received by Aqurat by no later than April 25, 2022 in accordance with the instructions on the notification form.

Please note that subscription warrants not exercised by April 25, 2022 will expire without any value. Holders who do not wish to exercise their subscription warrants have the opportunity to sell them by no later than today, April 21, 2022.

Investor presentations

CLS will make a presentation at the Redeye Investor Forum today, April 21, 2022. Information about the event is available on the Redeye website.

Advisor
Redeye AB is acting as the financial advisor and Aqurat Fondkommission AB is acting as the issuing institution for the transaction.

For further information, please contact:

Dan J. Mogren, Acting CEO Clinical Laserthermia Systems AB (publ)
 

Tel: +46 (0)705 90 11 40

Email: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy System, including associated specially designed sterile disposables, which is used for minimally invasive treatment of cancer tumors, pursuant to the respective regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and for treatment with imILT®, the Company’s interstitial laser thermal therapy with potential immunostimulatory effects. CLS is headquartered in Lund, Sweden, and has subsidiaries in Germany, the US and Singapore. CLS is listed on Nasdaq First North Growth Market under the ticker symbol CLS B. Its Certified Advisor (CA) is FNCA Sweden AB, tel: +46 (0)8 528 00 399. Email: info@fnca.se.

The information was submitted for publication, through the agency of the contact person, on 21-04-2022 08:31 CET.